TrialNeuropsychopharmacology reports2023

Long-term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow-up for 52 weeks (P06125)-Secondary publication.

Toshihiko Kinoshita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.